Open access · US-GOV
via ClinicalTrials.gov Clinical trial
A Phase I [18F]THK-5351 Positron Emission Computed Tomography Study of Biodistribution, Pharmacokinetics and Safety in Cognitively Healthy Subjects and Patients With Alzheimer's Disease
Authors not listed
Asan Foundation · 2017
Abstract
This is a study to evaluate biodistribution, pharmacokinetics and safety of \[18F\]THK-5351 positron emission computed tomography in Cognitively Healthy Subjects and Patients with Alzheimer's Disease.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- ClinicalTrials.gov
- Canonical
- link ↗
- Fetched
- 2026-11-11 MST
Cite this
APA
Anonymous. (2017). A Phase I [18F]THK-5351 Positron Emission Computed Tomography Study of Biodistribution, Pharmacokinetics and Safety in Cognitively Healthy Subjects and Patients With Alzheimer's Disease. <em>Asan Foundation</em>. https://clinicaltrials.gov/study/NCT03112096
Vancouver
Anonymous. A Phase I [18F]THK-5351 Positron Emission Computed Tomography Study of Biodistribution, Pharmacokinetics and Safety in Cognitively Healthy Subjects and Patients With Alzheimer's Disease. Asan Foundation. 2017.
BibTeX
@misc{anon2017APhase,
title = {A Phase I [18F]THK-5351 Positron Emission Computed Tomography Study of Biodistribution, Pharmacokinetics and Safety in Cognitively Healthy Subjects and Patients With Alzheimer's Disease},
author = {Anonymous},
journal = {Asan Foundation},
year = {2017},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Institute for Neurodegenerative Disorders 2009
Open access · US-GOV
An Exploratory, Open-label, Non-randomized Phase 0 Study to Evaluate Efficacy & Safety of MNI-513 Positron Emission Tomography for Detection/Exclusion of Cerebral Amyloid Beta in Patients w/ Alzheimer Disease Compared to Healthy Volunteers
AbbVie 2014
Open access · US-GOV
A Multiple-Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ABT-957 in Subjects With Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors
Chong Kun Dang Pharmaceutical 2019
Open access · US-GOV
An Open-label, Randomized, Multiple-dosing Parallel Study to Evaluate the Pharmacokinetics, Safety and Tolerability of CKD-355 With D797 and D324 in Healthy Subjects
The University of Texas Health Science Center at San Antonio 2021
Open access · US-GOV
Pilot Study to Investigate the Safety and Feasibility of AntiRetroviral Therapy for Alzheimer's Disease (ART-AD)
Abbott 2009
Open access · US-GOV
A Study of the Long-term Safety of ABT-089 for Subjects With Mild-to-moderate Alzheimer's Disease Who Participated in the M06-876 Study
University Hospitals Cleveland Medical Center 2012
Open access · US-GOV